0001209191-20-022241.txt : 20200401
0001209191-20-022241.hdr.sgml : 20200401
20200401181942
ACCESSION NUMBER: 0001209191-20-022241
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200330
FILED AS OF DATE: 20200401
DATE AS OF CHANGE: 20200401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Krognes Steve E.
CENTRAL INDEX KEY: 0001666236
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38311
FILM NUMBER: 20766794
MAIL ADDRESS:
STREET 1: 863 MITTEN ROAD, SUITE 102
CITY: BURLINGAME
STATE: CA
ZIP: 94010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Denali Therapeutics Inc.
CENTRAL INDEX KEY: 0001714899
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463872213
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 866-8548
MAIL ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-30
0
0001714899
Denali Therapeutics Inc.
DNLI
0001666236
Krognes Steve E.
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
CFO and Treasurer
Common Stock
2020-03-30
4
S
0
1428
19.48
D
1006488
D
Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.46 to $19.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
/s/ Tyler Nielsen, by power of attorney
2020-04-01